St. Jude Children’s Research Hospital shared a post on LinkedIn:
“Today, we take a moment to reflect on advances in HIV care and ongoing work to address gaps in treatment for children and adolescents.
At St. Jude, the HIV and Translational Medicine Program has been at the forefront of research and innovation for over forty years, striving to ensure that younger populations benefit from the same progress seen in adult care.
Through leadership in global clinical trials, Aditya Gaur, Division of HIV and Translational Medicine director, has helped drive the development and approval of long-acting injectable therapies for adolescents.
The IMPAACT Network’s multicenter study demonstrated positive outcomes for this approach, which has since received regulatory approval in the United States and Canada. This marks a significant milestone in expanding treatment options for youths, while making medicine easier to take.
‘There will always be a little bit of lag between when promising drugs or discoveries get approved for adults versus children and youths,’ Gaur explained. ‘But for this first all-injectable HIV treatment regimen, approval for use for adolescents in the United States and Canada was relatively soon after the approval for adults.’
The St. Jude commitment extends to younger children too, with research supporting the use of single-tablet regimens for those as young as two years old. These advances inform treatment guidelines and regulatory decisions, helping to close gaps in care.”
More posts from St. Jude Children’s Research Hospital.